Deutsch English
← back to archive
Industry & Engineering · 504 words · MN-260715-0059

China's pharma globalization problem

MuckyNews reading

Chinese pharma wants to go global, but it doesn't have the staff to pull it off. Companies like Jiangsu Hengrui and CanSino have big expansion plans, but internationally experienced talent for development and commercialization is nowhere to be found. What sounds like a standard HR headache is actually a structural bottleneck. China's rise as a testing hub for experimental medicines happened so fast that the industry simply neglected to build teams that can operate globally. In 2025, 88 percent of all China-sponsored clinical trials ran exclusively inside China. They tested extensively at home, but barely set foot outside. Now that they want to take their products to the global market, this domestic tunnel vision is catching up with them. And then there's the political reality: the US has already declined to approve some China-tested drugs, demanding multiregional trials that better reflect US patients and clinical practices. Who is supposed to design and manage these international trials when the very staff needed for that is missing, remains the open question. The takeaway is straightforward: a massive domestic testing lab doesn't make you a global player. When regulators abroad shut the door, the fastest domestic progress means nothing if you have no one who knows how to pick the lock.

Short version

  • What happened? Top Chinese drugmakers are struggling to find

internationally experienced staff for their global expansion.

  • Who is involved? Companies like Jiangsu Hengrui Pharmaceuticals and

CanSino Biologics, and US regulators.

  • Why does it matter? Fast domestic growth is hitting a wall without

global know-how and international trial designs.

  • What is still open? How companies will solve the talent gap and whether

they can clear regulatory hurdles going forward.

  • What is the real pressure point? The mismatch between massive domestic

scale and a total lack of global operational experience.

Perspective delta

  • japan_asia: The source frames the issue primarily as a structural growth

problem for the Chinese industry. It emphasizes the gap between China's rapid rise as a testing hub and its failure to build the workforce needed for the next step. US regulatory pushback is presented as an additional external hurdle. What is largely missing is the perspective of the Chinese companies themselves or the international talent market; the focus is squarely on observing an overheated market stumbling over its own limits.

Source base / limits

The source base is very narrow. There is only a single article from the Japan Times. This means single-source reporting with a clear regional slant (Japan/Asia). The text base is thin at roughly 930 characters. Any assessment from a Western, US, or Chinese perspective is entirely absent. The extent of the talent shortage and the specifics of the US regulatory block remain limited to this one outlet's framing.

Sources / basis

  • MuckyNews container ID: MN-20260715-059
  • Source outlets/stations: Japan Times
  • Perspective groups: japan_asia
  • Article count: 1
  • Source count: 1
  • Perspective count: 1
  • Approximate raw text size: 932 chars / approx. 233 tokens